

(19) AUSTRALIAN PATENT OFFICE

(54) Title	A process for the preparation of 1-(aminomethyl) cyclohexaneacetic acid		
(51) ⁶ International Patent Classification(s)	B01D 9/02 (2006.01) 227/18 C07C 227/18 20060101ALI2005100 (2006.01) 8BMEP C07C C07C 227/40 227/40 (2006.01) 20060101ALI2005122 C07C 227/42 0BMJP C07C (2006.01) 227/42 C07C 229/28 20060101ALI2005100 (2006.01) 8BMEP C07C B01D 9/02 229/28 20060101AFI2005122 20060101ALI2005122 0BMJP C07C 0BMJP PCT/EP01/13953		
(21) Application No:	2002229575	(22) Application Date:	2001.11.29
(87) WIPO No:	W002/44123		
(30) Priority Data			
(31) Number	(32) Date	(33) Country	
MI00A2608	2000.12.01	IT	
(43) Publication Date :	2002.06.11		
(43) Publication Journal Date :	2002.08.15		
(71) Applicant(s)	Erregierre S.P.A.		
(72) Inventor(s)	Ghezzi, Marcello, Belotti, Paolo, Ferrari, Massimo		
(74) Agent/Attorney	FISHER ADAMS KELLY, Level 29 Comalco Place 12 Creek Street, Brisbane, QLD, 4000		
(56) Related Art	WO 1998/028255		

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 June 2002 (06.06.2002)

PCT

(10) International Publication Number
WO 02/44123 A1

(51) International Patent Classification⁷: C07C 227/42, 227/18

(21) International Application Number: PCT/EP01/13953

(22) International Filing Date: 29 November 2001 (29.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: MI00A002608 1 December 2000 (01.12.2000) IT

(71) Applicant (for all designated States except US): ER-REGIERKE S.P.A. [IT/IT]; Via Francesco Baracca, 19, I 24060 San Paolo D'Argon (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): FERRARI, Massimo [IT/IT]; Via A. Locatelli, 7, I-24069 Cenate Sotto (IT); GHEZZI, Marcello [IT/IT]; Via Emilia, 7, I-24035 Curno (IT); BELOTTI, Paolo [IT/IT]; Via Delle Rimembranze, 2, I-24060 San Paolo D'Argon (IT).

(74) Agent: GERVASI, Gemma; Notarbartolo & Gervasi S.P.A., Corso di Porta Vittoria, 9, I-20122 Milan (IT).

(81) Designated States (national): AL, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GI, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, IV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, H, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/44123 A1

(54) Title: A PROCESS FOR THE PREPARATION OF 1-(AMINOMETHYL) CYCLOHEXANEACETIC ACID

(57) Abstract: A conversion process of gabapentin hydrochloride into gabapentin comprising: a) dissolution of gabapentin hydrochloride in a solvent in which the gabapentin hydrochloride and the gabapentin are completely soluble; and b) subsequent addition of an amine that allows the removal of the chloride ion from the solution containing gabapentin hydrochloride, by precipitation of the hydrochloride of the same amine, leaving the gabapentin in solution in free amino acid form.


A PROCESS FOR THE PREPARATION OF 1-(AMINOMETHYL) CYCLOHEXANEACETIC ACID

FIELD OF THE INVENTION

The present invention concerns a preparation process of 1-(aminomethyl) cyclohexaneacetic acid (GABAPENTIN).

PRIOR ART

GABAPENTIN, characterized by the following structural formula (I)



10 is an active principle mainly used in human therapy for the treatment of cerebral disease, namely epilepsy ("Drugs of the future", vol. 9, N° 6, 1984, pp. 418-419). Various processes are described in the art for the synthesis of this molecule. The American patent US 4,024,175 describes the preparation of GABAPENTIN starting from its hydrochloride salt, by treatment of an aqueous solution of the
15 latter with ion exchange resins, so as to remove the chloride ion and make the GABAPENTIN molecule available in a free amino acid form. The solution obtained at the end of the treatment is concentrated by distillation and the residue is recovered with alcohols to allow the isolation of GABAPENTIN. However, this process is complex and difficult, particularly due to the specific plant engineering
20 technology necessary to remove the chloride ion and make GABAPENTIN available in a free amino acid form.

The WO patent 98/28255 contains a description for the preparation of GABAPENTIN starting with its hydrochloride salt, in which elimination of the chloride ion is achieved in a different way from that described in the previous
25 patent. After having solubilized GABAPENTIN HYDROCHLORIDE in suitable non-aqueous solvents, an amine is added to the resultant solution which salinifies the chloride ion, making it soluble, and thus allowing the precipitation of GABAPENTIN in a new polymorphic form called "FORM III", which differs from the polymorphic

form known as "FORM II", which is that most widely used and sold. The GABAPENTIN obtained in the polymorphic form known as "FORM III", is necessarily transformed into the polymorphic form "FORM II" by treatment with alcohols. In addition, this treatment has the disadvantage of not being able to

5 recover the used amine and recycle it in the salification stage of the chloride ion. Therefore the need was felt for a preparation process of GABAPENTIN in the polymorphic form "FORM II", that of greatest use and commercial diffusion, starting with GABAPENTIN HYDROCHLORIDE, able to overcome the technical drawbacks connected with the need to use facilities for ion exchange resins, and

10 able to avoid passing through a polymorphic form "FORM III" of GABAPENTIN, different from the one on the market.

SUMMARY

A new separation process of GABAPENTIN in the polymorphic form "FORM II", has now been found, starting with GABAPENTIN HYDROCHLORIDE, capable of

15 overcoming technical drawbacks and those connected with the need to pass through an unusable crystalline form on sale, typical of the processes known in the art.

The applicant has unexpectedly and surprisingly found a new separation process of GABAPENTIN in the polymorphic form "FORM II", starting with GABAPENTIN

20 HYDROCHLORIDE, in which the chloride ion is eliminated by precipitating it as an insoluble salt, releasing GABAPENTIN in solution in free amino acid form.

DETAILED DESCRIPTION OF THE INVENTION

A conversion process of gabapentin hydrochloride into gabapentin therefore constitutes a purpose of the present invention comprising:

25 a) dissolution of gabapentin hydrochloride in a solvent in which the gabapentin hydrochloride and the gabapentin are completely soluble; and

b) subsequent addition of an amine that allows the removal of the chloride ion from the solution containing gabapentin hydrochloride, by precipitation of the hydrochloride of the same amine, releasing gabapentin in solution in free amino

30 acid form.

The solvent used at stage a) to completely solubilize gabapentin hydrochloride is preferably an aqueous solvent, more preferably a solvent consisting of at least

50% by weight of water, more preferably the solvent consists of at least 70% by weight of water, more preferably the solvent consists of at least 90% by weight of water, still more preferably the solvent is water.

The amine used at stage b) to remove the chloride ion is preferably an amine with 5 cycloalkyl or aryl substituents, more preferably it is selected from the group consisting of monocyclohexylamine, dicyclohexylamine, dibenzylamine, tricyclohexylamine, or their mixtures, still more preferably it is dicyclohexylamine.

The dissolution at stage a) is carried out at a temperature which depends on the solvent used and such as to allow the complete dissolution of gabapentin 10 hydrochloride and gabapentin, the temperature is preferably between 10° and 90°C, more preferably between 20° and 70°C, still more preferably between 30° and 50°C.


One of the particularly preferred embodiments of the conversion process of gabapentin hydrochloride into gabapentin, according to the present invention, 15 comprises, in addition to stages a) and b) as above, the removal stage c) by filtering the precipitate of the amine hydrochloride, from the solution containing gabapentin in free amino acid form, and the recovery of the amine by the alkali treatment of the amine hydrochloride to give the free amine which is recycled at stage b).

20 An additional preferred embodiment of the process, according to the present invention comprises, in addition to stages a), b) and c), as above, also stage d) wherein the solution containing gabapentin in free amino acid form is concentrated by distillation and the residue is recovered with alcohols selected from the group consisting of alkyl alcohols with one to four linear or branched carbon atoms, or 25 their mixtures, preferably ethyl alcohol, to give the isolation of gabapentin in polymorphic form "FORM II".


An additional preferred embodiment of the present invention comprises, in addition to the stages a), b), c) and d), also stage e) wherein gabapentin in polymorphic form "FORM II", isolated at stage d), is purified by treatment with alcohol selected

30 from the group consisting of alkyl alcohols with one to four linear or branched carbon atoms, or their mixtures, preferably a methyl alcohol/isopropyl alcohol mixture.

More particularly, according to the present invention, formula (II) gabapentin hydrochloride is used as a process intermediate




prepared due to the well known "Hoffmann rearrangement" reaction; this reaction consists in making the formula (III) compound react




with sodium or potassium hypochlorite, or sodium or potassium hypobromite to give an intermediate isocyanate that, because of the subsequent rearrangement, leads to the formation of gabapentin, isolated as a hydrochloride by acidification of the reaction environment with hydrochloric acid. The intermediate of formula (II)

15 gabapentin hydrochloride is completely solubilized in aqueous solvent, in this case water, and an amine is added to the solution obtained, in this case, dicyclohexylamine

of formula (IV)



able to move the chloride ion from gabapentin, it being salified; the dicyclohexylamine hydrochloride of formula (V) thus formed




5 is insoluble in aqueous environment, while gabapentin, thus rendered available in free amino acid form, vice versa proves soluble in this environment.

The suspension obtained is filtered recovering, on the one hand, an aqueous solution containing gabapentin in a free amino acid form and, on the other, a solid (cake) of amine hydrochloride, in this case, dicyclohexylamine hydrochloride,

10 which treated with strong bases, preferably hydroxides of alkaline metals, more preferably sodium hydroxide, thus allows the recovery of the amine, in this case, the dicyclohexylamine, and its recycling. The aqueous solution containing gabapentin is concentrated by distillation until the start of precipitation, with the residue taken back with an alkyl

15 alcohol, in this case ethanol. The suspension obtained is filtered, resulting in gabapentin in the polymorphic form "FORM II", with content of impurity of formula (VI)



of less than 0.05% by weight.

20 The process, subject of the present invention, also has the advantage that any presence of gabapentin hydrochloride or amine, in this case dicyclohexylamine, in the aqueous solution obtained after the removal of amine hydrochloride, in this case dicyclohexylamine hydrochloride, is absent in the alcoholic mother waters

from which gabapentin is isolated in the polymorphic form "FORM II".

The raw gabapentin obtained is treated under reflux with alcohol selected from the group consisting of alkyl alcohols with one to four carbon atoms, linear or branched, or their mixtures, preferably a methyl alcohol/isopropyl alcohol mixture, and the suspension thus obtained is brought to 0°C and filtered, obtaining gabapentin with polymorphic form "FORM II", verified by FTIR and X-Ray analyses, and having a HPLC purity in excess of 99.9%.

Below are some illustrative, but non-limiting examples of the present invention.

Example 1

10 100g of gabapentin hydrochloride are solubilized in 500g of deionized water and 90g of dicyclohexylamine are added while heating to 30°-50°C. An abundant precipitation of dicyclohexylamine hydrochloride is produced that is filtered with a Buchner funnel. The dicyclohexylamine hydrochloride solid is treated with sodium hydroxide, thus regarding the dicyclohexylamine that is

15 thus recovered and recycled in the separation stage of the chloride ion by precipitation, while the aqueous solution contains gabapentin in free amino acid form.

The aqueous solution obtained by filtering is distilled under reduced pressure, until the start of precipitation, and the residue is taken back with ethyl alcohol,

20 heated to 40°-50°C, and the suspension obtained is cooled for a few hours and filtered.

The solid obtained is vacuum dried at 30°-40°C, producing raw gabapentin in the polymorphic form "FORM II" with a formula (VI) impurity content of less than 0.05%. The yield is 80%.

Example 2

50 g of raw gabapentin arising from example 1 are suspended in 250 g of methyl alcohol and 125 g of isopropyl alcohol. It is heated under reflux for 30 minutes, and cooled at 20°-25°C for two hours and subsequently at 0°C for a further two hours. The suspension is filtered with a Buchner funnel and is

30 vacuum dried at 30°-40°C, producing gabapentin of polymorphic form "FORM II" with a HPLC purity greater than 99.85%, a content of lactam <0.10% and a content of chloride anions <100 ppm.

ADDITIONAL EXAMPLES CARRIED OUT ACCORDING TO THE
EUROPEAN PATENT APPLICATION No. 01 990454.9-1211

**EXAMPLE 1 carried out by using a mixture of dicyclohexylamine,
5 monocylohexylamine and dibenzylamine.**

A) PREPARATION OF RAW GABAPENTIN

75g of gabapentin hydrochloride and 450 g of demineralized water are charged into a 2 l flask and stirred. The mixture is then heated to 45-50°C until obtaining a complete solution of said salt. While maintaining at the 10 same temperature a mixture of 50 g dicycloesylamine 15 g monocylohexylamine and 15 g of dibenzylamine are subsequently dropped. Once the addition of the amines is completed, the reaction mixture containing the precipitate is stirred at the above temperature for about 15 minutes and thereafter it is cooled to 20-25°C and maintained at this 15 temperature for about 30 minutes. The precipitate is then filtered and washed with 52.5 g of cool water and the filtration water containing gabapentin are twice washed with 75g x2 of dichloromethane, which is then separated. The aqueous phase is distilled under vacuum until obtaining a pasty residue, which is stripped twice at 60-80°C under vacuum with 52.5 g 20 x2 of isopropanol. Then 375 g of methanol are added to the residue and heated until obtaining a complete solution. Then about 300 g of methanol are distilled under atmospheric pressure. The mixture is heated to 50-55°C and left at this temperature for about 30 minutes and subsequently it is cooled to 10-15°C and left at this temperature for 1 hour. The precipitate thus obtained 25 is filtered and washed with 52.5 g of methanol.
43 g of humid product are obtained showing a weight reduction equal to 5.7% corresponding to 40.5 g of crude gabapentin of formula (II). At the HPLC analysis it results that said product analogously with the crude product obtained in Example 1 reported in the aforementioned European 30 Patent Application, has a content of the byproduct of formula (VI) lower than 0.05%.

Preparation of gabapentin

40 g of crude gabapentin obtained as described above and 160g of methanol are charged into a 1 l flask, and heated under reflux for 30 minutes. After this treatment a complete solution of the crude product is not obtained. 110ml of solvent are distilled under atmospheric pressure and the mixture is cooled to 30-40°C. 8 g of isopropanol are slowly added to the residue. The mixture thus obtained is cooled to -5°C for 1 hour. The precipitate formed is filtered and washed with 20 g of isopropanol and dried at 30-40°C. 31 g of gabapentin form (II) are obtained, having a HPLC purity higher than 99.85%.

10

EXAMPLE 2 carried out by using a mixture of dicyclohexylamine, and monocyclohexylamine .

A) PREPARATION OF RAW GABAPENTIN

15

190 g of gabapentin hydrochloride and 900 g of demineralized water are charged into a 2 l flask and stirred. The mixture is then heated to 40-50°C until obtaining a complete solution of said salt. While maintaining at the same temperature a mixture of 130 g of dicycloesylamine and 26 g monocyclohexylamine are subsequently dropped. Once the addition of the amines is completed the reaction mixture containing the precipitate is stirred 20 at the above temperature for about 15 minutes and thereafter it is cooled to 20-25°C and maintained at this temperature for about 30 minutes. The precipitate is then filtered and washed with 105 g of cool water and the filtration water containing gabapentin are twice washed with 105 g x2 of dichloromethane, which is then separated. The aqueous phase is distilled under vacuum until obtaining a pasty residue, which is stripped twice at 60-80°C under vacuum with 105g x2 of isopropanol. Then 750 g of methanol are added to the residue and heated until obtaining a complete solution. Then about 600ml of methanol are distilled under atmospheric pressure. The mixture is heated to 50-55°C and left at this temperature for about 30 25 minutes and subsequently it is cooled to 10-15°C and maintained at this temperature for 1 hour. The precipitate thus obtained is filtered and washed with 105g of methanol.

30

93 g of humid product are obtained showing a weight reduction equal to 9,1% corresponding to 84.5 g of crude gabapentin form (II). At the HPLC analysis it results that said product, analogously with the crude product obtained in Example 1 reported in the above European Patent Application,

5 has a content of the byproduct of formula (VI) lower than 0.05%.

Preparation of gabapentin

80 g of crude gabapentin obtained as described above and 160g of methanol are charged into a 1 l flask, and heated under reflux for 30 minutes. After this

10 treatment a complete solution of the crude product is not obtained. 230 ml of solvent are distilled under atmospheric pressure and the mixture is cooled to 30-40°C. 8 g of isopropanol are slowly added to the residue. The mixture thus obtained is cooled to -5°C and maintained at this temperature for 1 hour. The precipitate formed is filtered and washed with 40 g of isopropanol and dried at 30-40°C. 64 g of gabapentin are obtained, having a HPLC purity

15 higher than 99.85%.

EXAMPLE 3 carried out by using dibenzylamine.

A) PREPARATION OF RAW GABAPENTIN

83 g of gabapentin hydrochloride (0.4 mol) coming from the synthetic process and 500 g of demineralized water are charged into a 1 l flask and stirred. The mixture is then heated to 45-50°C until obtaining a complete solution of said salt. While maintaining at the same temperature a mixture of 90.5 g of dibenzylamine are subsequently dropped. Once the addition of the amine is completed the reaction mixture containing the precipitate is stirred

25 at the same temperature for about 15 minutes and thereafter it is cooled to 20-25°C and maintained at this temperature for about 30 minutes. The precipitate is then filtered and washed with 55 g of cool water and the filtration water containing gabapentin are twice washed with 83g x2 of dichloromethane, which is then separated. The aqueous phase is distilled

30 under vacuum until obtaining a pasty residue, which is stripped twice at 60-80°C under vacuum with 58g x2 of isopropanol. Then 415 g of methanol are added to the residue and heated until obtaining a complete solution. Then

about 250 g of solvent are distilled under atmospheric pressure. The mixture is heated to 50-55°C and left at this temperature for about 30 minutes and subsequently it is cooled to 10-15°C and maintained at this temperature for 1 hour. The precipitate thus obtained is filtered and washed with 58 g of

5 methanol and dried at 30 -40°C.

31.2 g of crude gabapentin form (II). At the HPLC analysis it results that said product analogously with the crude product obtained in Example 1 contained in the instant European Application, has a content of the byproduct of formula (VI) lower than 0.05%.

10 *Preparation of gabapentin*

30 g of crude gabapentin obtained as described above and 120g of methanol are charged into a 0.5 l flask, and heated under reflux for 30 minutes. After this treatment a complete solution of the crude product is not obtained. 80ml

15 of solvent are distilled at atmospheric pressure and the mixture is cooled to 30-40°C. 6 g of isopropanol are slowly added to the residue. The mixture thus obtained is cooled to -5°C for 1 hour. The precipitate formed is filtered and washed with 20 g of isopropanol and dried at 30-40°C. 27 g of

gabapentin form (II) are obtained, having a HPLC purity higher than 99.85%.

CLAIMS:

1. A conversion process of gabapentin hydrochloride into gabapentin comprising:
 - 5 a) dissolution of gabapentin hydrochloride in a solvent in which the gabapentin hydrochloride and the gabapentin are completely soluble; and
 - 10 b) subsequent addition of an amine that allows the removal of the chloride ion from the solution containing gabapentin hydrochloride,
 - 15 10 by precipitation of the hydrochloride of the same amine, leaving gabapentin in solution in free amino acid form, wherein the solvent used in step (a) is water; and the amine used in step (b) is selected from the group consisting of monocyclohexylamine, dicyclohexylamine, dibenzylamine, tricyclohexylamine, and mixtures thereof.
 - 15 2. The process according to claim 2, wherein the amine is dicyclohexylamine.
 3. The process according to anyone of claims 1-2 further comprising the removal stage c) the removal by filtering of the precipitate of the amine hydrochloride, from the solution containing gabapentin in free amino acid 20 form.
 4. The process according to claim 3, wherein the hydrochloride of the amine is treated with alkalis in order to obtain the free amine which is recycled at stage b).
 5. The process according to claim 3 further comprising stage d) 25 wherein the solution containing gabapentin in free amino acid form is concentrated by distillation and the residue is taken back with alcohol selected from the group consisting of alkyl alcohols with one to four carbon atoms, linear or branched, or their mixtures, to give the isolation of gabapentin in polymorphic form "FORM II".
 - 30 6. The process according to claim 5, wherein the alcohol is methyl alcohol.
 7. The process according to claim 5, further comprising stage e)

wherein gabapentin in polymorphic form "FORM II", isolated at stage d), is further purified by treatment with alcohol selected from the group consisting of alkyl alcohols with one to four carbon atoms, linear or branched, or their mixtures.

- 5 8. The process according to claim 7, wherein the alcohol is a methyl alcohol/isopropyl alcohol mixture.
9. Gabapentin Form (II) with a purity measured by HPLC>99.85%, a content of lactam<0.10% and a content of chloride anion<100ppm prepared with the process according to anyone of claims 1 to 8.